Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1364914-39-5

Post Buying Request

1364914-39-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1364914-39-5 Usage

Description

exo-Granisetron (Granisetron Impurity F) is a chemical compound derived from the pharmaceutical drug Granisetron, which is primarily used as an antiemetic medication to prevent nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. As an impurity, exo-Granisetron may have different chemical properties or behaviors compared to the main compound, which can be significant in the context of drug development, quality control, and safety assessments.

Uses

Used in Pharmaceutical Industry:
exo-Granisetron (Granisetron Impurity F) is used as a reference standard for the identification, quality control, and purity assessment of Granisetron in the pharmaceutical industry. It helps ensure the safety and efficacy of the drug by providing a benchmark for comparison and analysis.
Used in Research and Development:
In the field of research and development, exo-Granisetron (Granisetron Impurity F) serves as a valuable tool for studying the chemical properties, stability, and potential interactions of Granisetron. This information can be crucial for optimizing the drug's formulation, dosage, and administration, as well as for identifying and mitigating any potential side effects or adverse reactions.
Used in Regulatory Compliance:
exo-Granisetron (Granisetron Impurity F) is utilized in the regulatory compliance process to ensure that the manufacturing and distribution of Granisetron meet the required standards and guidelines. By providing a reference for the detection and quantification of impurities, it helps maintain the overall quality and integrity of the drug, protecting public health and safety.
Used in Drug Development:
During the drug development process, exo-Granisetron (Granisetron Impurity F) can be employed to investigate the potential for new therapeutic applications or to identify and develop new drug candidates with similar or improved properties. This can lead to the discovery of novel treatments for various medical conditions, including those related to nausea and vomiting.

Check Digit Verification of cas no

The CAS Registry Mumber 1364914-39-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,4,9,1 and 4 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1364914-39:
(9*1)+(8*3)+(7*6)+(6*4)+(5*9)+(4*1)+(3*4)+(2*3)+(1*9)=175
175 % 10 = 5
So 1364914-39-5 is a valid CAS Registry Number.

1364914-39-5Relevant articles and documents

Preparation methods of 1H-indazol-3-carboxylic acid derivative, granisetron and lonidamine

-

, (2021/05/12)

The invention relates to preparation methods of a 1H-indazol-3-carboxylic acid derivative, granisetron and lonidamine. The 1H-indazol-3-carboxylic acid derivative is a compound with a structure shown in a formula (1) and a formula (2), and is mainly structurally characterized by having a 1H-indazol-3-carboxylic acid amide skeleton and a 1H-indazol-3-carboxylic ester skeleton. The 1H-indazol-3-carboxylic acid derivative can be synthesized by taking simple o-aminophenylacetic acid amide or o-aminophenylacetic acid ester as an initial raw material. The 1H-indazol-3-carboxylic acid derivative is a key intermediate for synthesizing a plurality of medicines, such as granisetron, lonidamine and the like. The synthesis method of the 1H-indazol-3-carboxylic acid derivative and the drug molecules glassetron and lonidamine is simple, the reaction condition is mild, the reaction speed is high, the yield is high, and purification is easy.

Catalytic direct amidations in: Tert -butyl acetate using B(OCH2CF3)3

Coomber, Charlotte E.,Laserna, Victor,Martin, Liam T.,Smith, Peter D.,Hailes, Helen C.,Porter, Michael J.,Sheppard, Tom D.

supporting information, p. 6465 - 6469 (2019/07/09)

Catalytic direct amidation reactions have been the focus of considerable recent research effort, due to the widespread use of amide formation processes in pharmaceutical synthesis. However, the vast majority of catalytic amidations are performed in non-polar solvents (aromatic hydrocarbons, ethers) which are typically undesirable from a sustainability perspective, and are often poor at solubilising polar carboxylic acid and amine substrates. As a consequence, most catalytic amidation protocols are unsuccessful when applied to polar and/or functionalised substrates of the kind commonly used in medicinal chemistry. In this paper we report a practical and useful catalytic direct amidation reaction using tert-butyl acetate as the reaction solvent. The use of an ester solvent offers improvements in terms of safety and sustainability, but also leads to an improved reaction scope with regard to polar substrates and less nucleophilic anilines, both of which are important components of amides used in medicinal chemistry. An amidation reaction was scaled up to 100 mmol and proceeded with excellent yield and efficiency, with a measured process mass intensity of 8.

CRYSTALLINE GRANISETRON BASE AND PRODUCTION PROCESS THEREFOR

-

Page/Page column 3, (2008/12/07)

Provided is crystalline granisetron base form I and processes for producing crystalline granisetron base form I, which is suitable for preparing, e.g., granisetron salts such as, e.g., the hydrochloride salt. Also provided is a process for producing a salt of granisetron from crystalline granisetron base form I.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1364914-39-5